

INTERESTING RETINAL CASES/VIDEO PROGRAM

WEDNESDAY, SEPTEMBER 10, 2025

- 12:00 PM WELCOME
JENNIFER LIM, MD
- MODERATORS: MARK JOHNSON, MD AND KIMBERLY STEPIEN, MD**
- 12:05 PM VITRECTOMY FOR VITREOUS OPACITY ASSOCIATED WITH AN INTRAOCULAR MASS IN 6-YEAR-OLD BOY
SATORU KASE, MD, PhD
- 12:10 PM AN ONCOLOGY CASE FROM MEMORIAL SLOAN KETTERING CANCER CENTER
DAVID ABRAMSON, MD
- 12:15 PM RAPIDLY PROGRESSIVE BULLS-EYE MACULOPATHY WITH IVOSPEMIN. AN EXPERIMENTAL TREATMENT FOR PANCREATIC ADENOCARCINOMA.
IAN MCALLISTER, MD, PhD
- 12:20 PM MOSAIC ART
KIMBERLY STEPIEN, MD
- 12:25 PM A CASE OF TOO LITTLE TOO LATE
MARK JOHNSON, MD
- 12:30 PM A (NOT SO) ROUTINE CASE
ROBERT SISK, MD
- 12:35 PM NOVEL THERAPY FOR RITUXIMAB-INDUCED CYTOMEGALOVIRUS RETINITIS
ALAN PALESTINE, MD
- 12:40 PM WHICH DRYING AGENT IS THE BEST NOW?
JACLYN KOVACH, MD
- 12:45 PM MULTIPLE EVANESCENT WHITE DOT SYNDROME FOLLOWING COVID-19 INFECTION: A CASE REPORT
MICHAEL COLUCCIello, MD
- 12:50 PM A RARE CASE OF WHITE DOT SYNDROME
NAUMAN CHAUDHRY, MD
- 12:55 PM RETINAL DEVASTATING CHANGE DURING JAK INHIBITOR USE TO TREAT GVHD
SUSUMU ISHIDA, MD, PhD
- 1:00 PM "I SEE SPOTS"
RUKHSANA MIRZA, MD
- 1:05 PM UNKNOWN
J. FERNANDO AREVALO, MD, PhD, FACS
- 1:10 PM RETINOPATHY OF PREMATURITY IN HALF OF THE EYE
XI CHEN, MD, PhD
- 1:15 PM HIGH-DOSE INTRAOCULAR DELIVERY OF EPINEPHRINE BY AN AUTO-INJECTOR IN A CHILD CAUSING RETINAL TRAUMA WITHOUT ARTERIAL OCCLUSION
RITHWICK RAJAGOPAL, MD, PhD

MODERATORS: LEJLA VAJZOVIC, MD AND MATTHEW JOHNSON, MD

- 1:20 PM IS THIS REALLY FAMILIAL BIRDSHOT?
GEOFF WILLIAMS, MD, FRCSC
- 1:25 PM MYSTERY CASE
MICHELLE LIANG, MD
- 1:30 PM A RING OF DECEPTION
BRADLEY SMITH, MD
- 1:35 PM FAR FROM THE MADDING CROWD: A CASE OF AN UNUSUAL SYSTEMIC DISEASE WITH RETINAL MANIFESTATIONS.
QUAN DONG NGUYEN, MD, MSc
- 1:40 PM NO, I'M NOT TALKING ABOUT THE ALPS!
GLENN JAFFE, MD
- 1:45 PM RECURRENT SUBMACULAR HEMORRHAGE
JONATHAN CHANG, MD
- 1:50 PM NEONATAL VITREOUS HEMORRHAGE: WHEN IT IS NOT ROP
VAIDEHI DEDANIA, MD
- 1:55 PM MYSTERY FLUID
MICHAEL OBER, MD
- 2:00 PM A GUEST AT THE MASQUERADE BALL
COLIN MCCANNEL, MD
- 2:05 PM MACULOPATHY
ANITA AGARWAL, MD
- 2:10 PM A DIAGNOSTIC MYSTERY: VISION LOSS IN A HEMODIALYSIS PATIENT
LEJLA VAJZOVIC, MD
- 2:15 PM PVR THAT MELTS AWAY
SCOTT OLIVER, MD
- 2:20 PM RETROBULBAR HEMORRHAGE AFTER TREATMENT FOR CYSTOID MACULAR EDEMA
MANJU SUBRAMANIAN, MD

VIDEO PROGRAM

- 2:25 PM LONG-TERM PERFLUOROCARBON LIQUID IN TRAUMATIC RETINAL DETACHMENT
MARIA BERROCAL, MD
- 2:30 PM RECURRENT HIGH MYOPIC MACULAR HOLE RETINAL DETACHMENT WITH PVR
TAMER MAHMOUD, MD, PhD
- 2:35 PM AMNIOTIC MEMBRANE IN TRACTIONAL RETINAL DETACHMENT IN PROLIFERATIVE DIABETIC RETINOPATHY
ZOFIA ANNA NAWROCKA (VEL MICHALEWSKA), MD, PhD
- 2:40 PM PERFLUORO-N-OCTANE (PFO)-GUIDED RETINECTOMY TO IMPROVE THE SINGLE SURGERY ANATOMIC SUCCESS (SSAS) RATE IN PATIENTS WITH PROLIFERATIVE VITREORETINOPATHY (PVR)

AJAY KURIYAN, MD, MS

- 2:45 PM REMOVAL OF RETAINED SUBFOVEAL PFO FOLLOWING A GIANT RETINAL TEAR REPAIR
CHRISTINA WENG, MD, MBA
- 2:50 PM TENSION IN THE CAPSULE: NOT YOUR TYPICAL IOL EXCHANGE
MATTHEW CUNNINGHAM, MD
- 2:55 PM REFRESHMENT BREAK

SCIENTIFIC PROGRAM

WEDNESDAY, SEPTEMBER 10, 2025

GENETIC DISEASES, DYSTROPHIES, DEGENERATIONS

MODERATORS: MARK PENNESI, MD AND CHRISTINE KAY, MD

- 3:20 PM NOVEL PATHOGENIC VARIANTS IN IFT140 AND IFT172 GENES
TALIA KADEN, MD
- 3:23 PM NORTH CAROLINA MACULAR DYSTROPHY, HAPLOTYPE ANALYSIS OF 31 FAMILIES SHOWS SINGLE FOUNDERS FOR EACH MUTATION
KENT SMALL, MD
- 3:26 PM GENOTYPE-PHENOTYPE CORRELATIONS AND OCULAR OUTCOMES IN STICKLER SYNDROME
NITA VALIKODATH, MD, MS
- 3:30 PM DISCUSSION
- 3:32 PM A NOVEL, LONG-ACTING, SMALL MOLECULE PKM2 ACTIVATOR AND ITS POTENTIAL BROAD APPLICATION AGAINST PHOTORECEPTOR DEGENERATION
WARREN PAN, MD, PhD
- 3:36 PM LENTIVIRUS-BASED NEUROPROTECTIVE GENE THERAPY FOR RETINITIS PIGMENTOSA: RESULTS FROM THE PHASE I/IIA INVESTIGATOR-INITIATED CLINICAL TRIAL OF DVC1-0401
YUSUKE MURAKAMI, MD, PhD
- 3:39 PM PRODYGY: A FIRST-IN-HUMAN TRIAL OF ROD-DERIVED CONE VIABILITY FACTOR (RDCVF) GENE THERAPY IN SUBJECTS WITH ROD-CONE DYSTROPHY
JOSEPH MARTEL, MD
- 3:42 PM COMBINED DISCUSSION
- 3:44 PM REMAIN: 152-WEEK EXTENDED ANALYSIS FROM THE MCO-010 OPTOGENETIC THERAPY FOR RETINITIS PIGMENTOSA RESTORE STUDY
CHRISTINE KAY, MD
- 3:49 PM DISCUSSION
- 3:51 PM A PHASE 3 STUDY OF TINLAREBANT, AN ORAL THERAPY DESIGNATED FOR STARGARDT DISEASE: INTERIM ANALYSIS
QUAN DONG NGUYEN, MD, MSc

- 3:56 PM DISCUSSION
- 3:58 PM GILDEURETINOL SLOWS PROGRESSION OF STARGARDT DISEASE: THE TEASE PROGRAM
PHILIP FERRONE, MD
- 4:03 PM DISCUSSION
- 4:05 PM SAFETY AND EFFICACY OF OCU400 GENE THERAPY FOR RETINITIS PIGMENTOSA: TWO-YEAR FOLLOW-UP OF PHASE 1/2 CLINICAL TRIAL
HOSSEIN AMERI, MD, PhD, FRCSI, MRCOphth
- 4:10 PM DISCUSSION
- 4:12 PM SUBRETINAL GENE THERAPY LARU-ZOVA FOR X-LINKED RETINITIS PIGMENTOSA (XLRP): PHASE 2 DAWN TRIAL, PRELIMINARY MONTH 9 RESULTS
RAJIV ANAND, MD
- 4:17 PM DISCUSSION

PEDIATRICS

MODERATORS: CYNTHIA TOTH, MD AND NIMESH PATEL, MD

- 4:19 PM DEPTH-RESOLVED AXIAL ANALYSIS OF RETINAL VASCULATURE DEVELOPMENT IN VERY PREMATURE INFANTS
YE HE, MD, PhD
- 4:24 PM FOVEAL DEVELOPMENT IN PREMATURITY: A LONGITUDINAL STUDY DURING THE FIRST YEAR OF LIFE AND ITS ASSOCIATION WITH VISUAL ACUITY
XIAO YI ZHOU, MD
- 4:27 PM COMBINED DISCUSSION
- 4:29 PM RETINAL IMAGING BIOMARKERS AND CORRELATION TO SYSTEMIC DISEASE ACTIVITY IN PEDIATRIC SICKLE CELL DISEASE
NIMESH PATEL, BS, MD
- 4:34 PM DISCUSSION
- 4:36 PM SURGICAL MANAGEMENT OF TRACTION RETINAL DETACHMENT AND EPIRETINAL MEMBRANE IN COATS DISEASE: AN INTERNATIONAL MULTICENTER STUDY
TADASHI YOKOI, MD, PhD
- 4:40 PM DISCUSSION

RETINAL VASCULAR DISEASE

MODERATORS: SUSANNA PARK, MD AND ADRIENNE SCOTT, MD

- 4:42 PM SAFETY AND FEASIBILITY ANALYSIS OF A RANDOMIZED, PROSPECTIVE, DOUBLE-MASKED, SHAM-CONTROLLED STUDY OF INTRAVITREAL AUTOLOGOUS BONE MARROW CD34+ STEM CELL THERAPY FOR CENTRAL RETINAL VEIN OCCLUSION

SUSANNA PARK, MD, PhD

- 4:47 PM DISCUSSION
- 4:49 PM RISK FACTORS ASSOCIATED WITH DEVELOPMENT OR PROGRESSION OF PROLIFERATIVE SICKLE CELL RETINOPATHY
ADRIENNE SCOTT, MD
- 4:54 PM DISCUSSION
- 4:56 PM AFLIBERCEPT 8 MG IN TREATMENT- NAÏVE MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION: PRIMARY ENDPOINT RESULTS FROM THE PHASE 3 QUASAR STUDY
SEENU HARIPRASAD, MD
- 5:00 PM DISCUSSION
- 5:02 PM ASSOCIATION OF EARLY MACULAR LEAKAGE RESOLUTION WITH EXTENDED DOSING INTERVALS IN PATIENTS WITH RVO: A POST HOC ANALYSIS OF THE BALATON/COMINO TRIALS
IVAN SUNER, MD, MBA
- 5:06 PM DISCUSSION
- 5:08 PM ADJOURN

SCIENTIFIC PROGRAM

THURSDAY, SEPTEMBER 11, 2025

IMAGING

MODERATORS: JENNIFER LIM, MD AND GLENN YIU, MD

- 7:30 AM EFFECTS OF AGE, SEX, AND AXIAL LENGTH ON MACULAR STRUCTURE AND PERFUSION IN NORMAL EYES
SATORU KASE, MD, PhD
- 7:34 AM NOVEL METHOD OF DETECTION OF BIREFRINGENT OCULAR AMYLOIDOSIS DEPOSITS USING MONOCHROMATIC WAVELENGTHS OF SCANNING LASER OPHTHALMOSCOPY
SIDRA ZAFAR, MD
- 7:38 AM ULTRASONIC IMAGING OF ORBITAL ARTERIES, VEINS, AND TUMORS: MAJOR CHANGES IN B-SCAN IMAGING
YALE FISHER, MD
- 7:42 AM DISCUSSION
- 7:44 AM HIGH-RESOLUTION VISUALIZATION OF POSTERIOR VITREOUS USING SWEEP-SOURCE OCT AND CUSTOM SOFTWARE ENHANCEMENT
DAVID WONG, MD
- 7:48 AM DISCUSSION

- 7:50 AM IN VIVO ASSESSMENT OF PERIPHERAL VITREOUS WITH ULTRA-WIDEFIELD SWEEP-SOURCE OPTICAL COHERENCE TOMOGRAPHY IN RHEGMATOGENOUS RETINAL DETACHMENT.
MIGUEL CRUZ PIMENTEL, MD
- 7:54 AM DISCUSSION
- 7:56 AM OCT MEASUREMENTS OF THE SUPRACHOROIDAL SPACE IN HEALTH AND DISEASE
GLENN YIU, MD, PhD
- 8:00 AM DISCUSSION
- 8:02 AM CAPILLARY FREE ZONE (CFZ) ANALYSIS AS A QUANTITATIVE BIOMARKER FOR DETECTION OF EARLY DIABETIC RETINOPATHY
JENNIFER LIM, MD
- 8:07 AM DISCUSSION
- 8:09 AM OPTICAL COHERENCE TOMOGRAPHY TO FUNCTION (OCT FX) DELPHI STUDY: ESTABLISHING A GLOBAL CONSENSUS ON ELLIPSOID ZONE (EZ) MEASUREMENT AND ANALYSIS IN AGE-RELATED MACULAR DEGENERATION (AMD)
PETER KAISER, MD
- 8:14 AM DISCUSSION
- 8:17 AM STELLATE NONHEREDITARY IDIOPATHIC FOVEOMACULAR RETINOSCHISIS (SNIFR) AND CENTRAL ANOMALOUS RETINOSCHISIS WITH MID-PERIPHERAL TRACTION (CARPET)
DAVID SARRAF, MD
- 8:22 AM DISCUSSION

OTHER MACULAR DISEASE

MODERATORS: SOPHIE BAKRI, MD AND ELIZABETH ROSSIN, MD, PHD

- 8:24 AM RITONAVIR RETINAL TOXICITY: A LITERATURE REVIEW AND INSTITUTIONAL IMAGING ANALYSIS AT AN URBAN ACADEMIC CENTER
KYLE KOVACS, MD
- 8:28 AM OCCURRENCE OF EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN-LIKE APPEARANCE IN PATIENTS WITH RHEUMATIC FEVER: A CROSS-SECTIONAL STUDY
RODRIGO JORGE, MD, PhD
- 8:32 AM DISCUSSION
- 8:34 AM UPDATE ON GENETICS OF CENTRAL SEROUS CHORIORETINOPATHY: NEW GENETIC ASSOCIATIONS REINFORCE THE IMPORTANCE OF THE CHOROIDAL VASCULATURE, SCLERA AND CIRCULATING PROTEINS.
ELIZABETH ROSSIN, MD, PhD
- 8:39 AM DISCUSSION
- 8:41 AM INTRAVITREAL FARICIMAB FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO CENTRAL SEROUS CHORIORETINOPATHY
JAY CHHABLANI, MD

- 8:45 AM TREATMENT-RESISTANT CHRONIC CENTRAL SEROUS CHORIORETINOPATHY RESPONDS TO SUBTHRESHOLD LASER THERAPY: A PROSPECTIVE CASE SERIES
AMIRFARBOD YAZDANYAR, MD, PhD
- 8:49 AM COMBINED DISCUSSION
- 8:53 AM POOLED FUNCTIONALITY DATA OF REVAKINAGENE TARORETCEL-LWEY IN PATIENTS WITH MACULAR TELANGIECTASIA TYPE 2
W. CLARK, MD
- 8:58 AM THE EFFECT OF BASELINE ELLIPSOID ZONE AREA LOSS ON TREATMENT RESPONSE OF REVAKINAGENE TARORETCEL-LWEY (NT-501) IN MACULAR TELANGIECTASIA TYPE 2
SOPHIE BAKRI, MD
- 9:03 AM COMBINED DISCUSSION
- 9:07 AM PREVALENCE OF SYSTEMIC COMORBIDITIES AND OCULAR INTERVENTIONS IN PATIENTS WITH BILATERAL RETINAL TELANGIECTASIA
KAREN WAI, MD
- 9:11 AM NEW AAO RECOMMENDATIONS ON SCREENING FOR HYDROXYCHLOROQUINE RETINOPATHY
MICHAEL MARMOR, MD
- 9:16 AM DISCUSSION
- 9:19 AM PATHOGENIC MECHANISMS OF IMMUNE CHECKPOINT INHIBITOR (ICI)-ASSOCIATED CHOROIDAL AND RETINAL ADVERSE REACTIONS
MARK JOHNSON, MD
- 9:23 AM DRAMATIC WORSENING OF MULTIFOCAL VITELLIFORM PARAVASCULAR RETINOPATHY ASSOCIATED WITH DE NOVO APPEARANCE OF BESTROPHIN ANTIBODIES
JASON MILLER, MD, PhD
- 9:27 AM COMBINED DISCUSSION
- 9:30 AM **REFRESHMENT BREAK**

SURGERY I

MODERATORS: SUNIR GARG, MD AND CHRISTINA WENG, MD

- 9:45 AM THE IMPACT OF PERIOPERATIVE BLOOD PRESSURE ON POSTOPERATIVE INTRAOCULAR HEMORRHAGE
MANJU SUBRAMANIAN, MD
- 9:49 AM DISCUSSION
- 9:51 AM OUTCOMES OF EARLY AND DELAYED SCLERAL WINDOWS FOR UVEAL EFFUSION SYNDROME
VENKATKRISH KASETTY, MD

9:55 AM	DISCUSSION
9:58 AM	FACTORS ASSOCIATED WITH VISUAL AND ANATOMIC OUTCOMES OF SUPRACHOROIDAL HEMORRHAGE: A RETROSPECTIVE STUDY FROM TWO SITES BENJAMIN KIM, MD
10:02 AM	DISCUSSION
10:05 AM	A NOVEL PLATFORM FOR TARGETED SUPRACHOROIDAL DELIVERY: ASSESSMENT OF PROTOTYPE IN PIG EYES. RAJEEV MUNI, MD, MSc, FRCSC
10:10 AM	DISCUSSION
10:12 AM	LOW OPTICAL DENSITY RATIO OF SUBRETINAL FLUID AT PRESENTATION PREDICTS FAVORABLE OUTCOMES IN ACUTE RHEGMATOGENOUS RETINAL DETACHMENT ADIEL BARAK, MD
10:16 AM	DISCUSSION
10:18 AM	CHOROIDAL THICKNESS AFTER RETINAL DETACHMENT REPAIR WITH PERSISTENT SUBRETINAL FLUID LUIZ LIMA, MD
10:22 AM	DISCUSSION
10:25 AM	PREDICTORS OF PRIMARY ANATOMIC REATTACHMENT WITH PNEUMATIC RETINOPEXY FOR RHEGMATOGENOUS RETINAL DETACHMENT AURORA PECAKU, MD
10:29 AM	DISCUSSION
10:31 AM	SURGICAL OUTCOMES AND UTILITY OF FELLOW EYE TREATMENT AMONG PATIENTS WITH RETINAL DETACHMENT DUE TO GIANT RETINAL TEAR: A MULTICENTER STUDY SUNIR GARG, MD, FACS
10:36 AM	DISCUSSION
10:39 AM	SURGICAL OUTCOMES OF RETINAL DETACHMENT REPAIR IN VIRAL RETINITIS: A MULTICENTER U.S. STUDY ALEJANDRO ITZAM MARIN, MD
10:43 AM	DISCUSSION
10:45 AM	POSTOPERATIVE DAY 0 AS A SUBSTITUTE FOR POSTOPERATIVE DAY 1 EXAMINATION FOLLOWING VITREORETINAL SURGERY: A COMPARATIVE PROSPECTIVE STUDY CHRISTINA WENG, MD, MBA
10:50 AM	DISCUSSION
10:52 AM	EARLY VITRECTOMY VS TAP-AND-INJECT FOR POST-INJECTION ENDOPHTHALMITIS: AN INTERNATIONAL MATCHED CASE CONTROL STUDY YOSHIHIRO YONEKAWA, MD

10:57 AM DISCUSSION

SOCIO-ECONOMIC

MODERATORS: ANTONIO CAPONE, MD AND BRITTANY POWELL, MD

10:59 AM OPHTHALMOLOGY COVERAGE FOR EMERGENCY AND TRAUMA CALL: FACTORS THAT IMPROVE PATIENT CARE AND TRAUMA MEDICAL DIRECTOR SATISFACTION
BRITTANY POWELL, MD, FACS

11:03 AM DISCUSSION

11:05 AM ECONOMIC IMPACT OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PRIOR AUTHORIZATION PROCESS
ELLA LEUNG, MD

11:09 AM ACCURACY OF INITIAL ANTI-VEGF TREATMENT SELECTION IN NEWLY DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: RETINAL SPECIALIST CHOICE VERSUS STEP THERAPY
PRITHVI BOMDICA, MD, MBA

11:13 AM COMBINED DISCUSSION

11:17 AM INCIDENCE OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INTRAVITREAL INJECTIONS FOR NON-FOOD AND DRUG ADMINISTRATION APPROVED INDICATIONS
SCOTT FRIEDMAN, MD

11:21 AM CHANGES IN ACCESS AND UTILIZATION OF FARICIMAB, AFLIBERCEPT, RANIBIZUMAB AND BEVACIZUMAB ACROSS INSURERS IN THE UNITED STATES
RAVI PARIKH, MD MPH

11:25 AM COMBINED DISCUSSION

AMD I

MODERATORS: DEEBA HUSAIN, MD AND THOMAS WUBBEN, MD, PHD

11:29 AM THE ROLE OF MYELOID CELL HETEROGENEITY DURING SPONTANEOUS CHOROIDAL NEOVASCULARIZATION IN VLDLR KNOCKOUT MICE
JEREMY LAVINE, MD, PhD

11:34 AM DISCUSSION

11:36 AM TARGETING PHOTORECEPTOR METABOLIC ADAPTATIONS IN AGE-RELATED MACULAR DEGENERATION BY MODULATING PYRUVATE KINASE M2 SLOWS PROGRESSION OF DISEASE
THOMAS WUBBEN, MD, PhD

11:41 AM DISCUSSION

11:43 AM LONG-TERM "CEREAL WORLD" WESTERN-STYLE DIET AND MEDITERRANEAN-TYPE DIET INFLUENCE CHOROIDAL NEOVASCULARIZATION AND SUBRETINAL MICROGLIA/MACROPHAGE INFILTRATION VIA GUT MICROBIOME MODULATION
DIMITRA SKONDRA, MD, PhD

11:48 AM	DISCUSSION
11:50 AM	METABOLIC PROFILING OF NORMAL HUMAN RETINAL AND CHOROIDAL TISSUE AND CORRELATIONS WITH VITREOUS HUMOR AND SERUM DEEBA HUSAIN, MD
11:55 AM	PLASMA METABOLOMIC PROFILES ASSOCIATED WITH FIVE-YEAR PROGRESSION OF AGE-RELATED MACULAR DEGENERATION INES LAINS, MD, PhD
12:00 PM	COMBINED DISCUSSION
12:04 PM	ASSOCIATION BETWEEN SYSTEMIC COMPLEMENT LEVELS AND MULTIMODAL IMAGING BIOMARKERS IN INTERMEDIATE AGE-RELATED MACULAR DEGENERATION TALISA DE CARLO FOREST, MD
12:09 PM	DISCUSSION
12:11 PM	FELLOWSHIP RESEARCH AWARD INTRODUCTION: ADRIENNE SCOTT, MD MULTIMODAL AI INTEGRATION OF LIQUID BIOPSY PROTEOMICS AND ELECTRONIC HEALTH RECORD DATA IN DIABETIC RETINOPATHY JONATHAN B. LIN, MD, PhD
12:26 PM	RETINA RESEARCH FOUNDATION AWARD INTRODUCTION: JENNIFER LIM, MD CHARLES L. SCHEPENS LECTURE: HUMAN PHOTORECEPTOR TOPOGRAPHY AND THE EVOLUTIONARY BIOLOGY OF DEPOSIT-DRIVEN AMD CHRISTINE CURCIO, PhD
1:00 PM	LUNCH
1:45 PM	DESSERT AND POSTER VIEWING SESSION 1

INFLAMMATION

MODERATORS: ANITA AGARWAL, MD AND MARK BREAZZANO, MD, FACS

2:30 PM	ANTISEPSIS FOR INTRAVITREAL INJECTION: IN VITRO CHLORHEXIDINE AND POVIDONE-IODINE EFFICACY AND CORNEAL TISSUE VIABILITY NICOLAS YANNUZZI, MD
2:34 PM	DISCUSSION
2:36 PM	VALIDATION OF AN UNBIASED METAGENOMIC SEQUENCING APPROACH FOR DIAGNOSIS OF INFECTIOUS UVEITIS JENNIFER HU, MD
2:40 PM	DISCUSSION

- 2:42 PM BISPECIFIC TRAP-ANTIBODY INHIBITING INTERLEUKIN-6 AND VASCULAR ENDOTHELIAL GROWTH FACTOR (KSI-101): FIRST-TIME RESULTS FROM THE PHASE 1B APEX STUDY IN PATIENTS WITH MACULAR EDEMA SECONDARY TO INFLAMMATION (MESI)
CHARLES WYKOFF, MD, PhD
- 2:47 PM DISCUSSION
- 2:49 PM FURTHER PATHOGENIC CONCEPTS IN DIFFUSE UNILATERAL SUBACUTE NEURORETINITIS (DUSN)
ANITA AGARWAL, MD
- 2:53 PM DISCUSSION
- 2:55 PM COMPARATIVE OUTCOMES OF ENDOPHTHALMITIS IN TRABECULECTOMY AND TUBE SHUNT SURGERY: A NINE-YEAR REVIEW OF CLINICAL COURSE AND MANAGEMENT
SAMIR PATEL, MD
- 2:59 PM LONG TERM VISUAL AND SURGICAL OUTCOMES IN 33 EYES WITH NON-INFECTIOUS UVEITIS REQUIRING SECONDARY LENS IMPLANTATION
SRUTHI AREPALLI, MD
- 3:03 PM COMBINED DISCUSSION
- 3:05 PM UTILITY OF CMV RETINITIS SCREENING FOR PATIENTS WITH CMV VIREMIA: MULTICENTER INVESTIGATION
MARK BREAZZANO, MD, FACS
- 3:09 PM LONG-TERM OUTCOMES OF COMBINATION SYSTEMIC AND INTRAVITREAL ANTIVIRAL THERAPY IN THE MANAGEMENT OF ACUTE RETINAL NECROSIS
ZACHARY KROEGER, MD
- 3:13 PM COMBINED DISCUSSION
- 3:15 PM LATE BREAKERS SESSION 1
- 3:30 PM **REFRESHMENT BREAK**

DIABETES I

MODERATORS: DIANA DO, MD AND AMANI FAWZI, MD

- 4:00 PM SUPRACHOROIDAL AVORALSTAT, A PLASMA KALLIKREIN INHIBITOR, REDUCES MEMBRANE PERMEABILITY IN VITRO AND STOPS VASCULAR LEAKAGE IN A WELL-ESTABLISHED RABBIT MODEL
RAJ MATURI, MD
- 4:05 PM DISCUSSION
- 4:07 PM THE INFLAMMATORY MEDIATORS IN THE PATHOPHYSIOLOGY OF DIABETIC RETINOPATHY (INSPIRE):BASELINE AND 1-YEAR RESULTS
STEPHEN KIM, MD
- 4:12 PM DISCUSSION

4:14 PM	HYPOGLYCEMIA ENHANCES RISK AND PROGRESSION OF DIABETIC RETINOPATHY SHREE KURUP, MD
4:19 PM	DISCUSSION
4:21 PM	HYPERTENSION IN DIABETIC RETINOPATHY: IMPACT ON VISION, OCT AND OCTA AMANI FAWZI, MD
4:26 PM	DISCUSSION
4:28 PM	REFINING DIABETIC RETINOPATHY SEVERITY AND RISK OF WORSENING BASED ON ULTRAWIDE FIELD FLUORESCCEIN ANGIOGRAPHY PAOLO ANTONIO SILVA, MD
4:33 PM	DISCUSSION
4:35 PM	LONGITUDINAL QUANTITATIVE ULTRA-WIDEFIELD RETINAL LEAKAGE ASSESSMENT AND MACULAR VOLUMETRIC FLUID OUTCOMES FOLLOWING A SINGLE AXITINIB HYDROGEL (OTX-TKI) IN THE HELIOS TRIAL FOR NON-PROLIFERATIVE DIABETIC RETINOPATHY JUSTIS EHLERS, MD
4:40 PM	DISCUSSION
4:42 PM	EFFICACY AND SAFETY OUTCOMES OVER 12 WEEKS WITH OCS-01 EYE DROPS IN DME FROM DIAMOND PHASE 2/3 TRIAL: FOCUS ON SUBGROUP BY LENS STATUS DIANA DO, MD
4:47 PM	DISCUSSION
4:49 PM	VERONA: END-OF-STUDY RESULTS FROM A PHASE 2 TRIAL OF EYP-1901 (VOROLANIB INTRAVITREAL INSERT) VERSUS AFLIBERCEPT FOR DIABETIC MACULAR EDEMA ASHKAN ABBEY, MD
4:54 PM	DISCUSSION
4:56 PM	THE ASPIRE PHASE 2B TRIAL OF SENOLYTIC UBX1325 (FOSELUTOCLAX) IN DIABETIC MACULAR EDEMA HANI SALEHI-HAD, MD
5:01 PM	DISCUSSION
5:03 PM	AUTOMATED QUANTIFICATION OF RETINAL FLUID VOLUME IN PATIENTS WITH DIABETIC MACULAR EDEMA: ANALYSIS OF FARICIMAB VS AFLIBERCEPT IN YOSEMITE/RHINE COLIN TAN, MBBS, FRCSEd (Ophth), MMed (Ophth)
5:07 PM	DISCUSSION
5:09 PM	ADJOURN

SCIENTIFIC PROGRAM

FRIDAY, SEPTEMBER 12, 2025

ARTIFICIAL INTELLIGENCE

MODERATORS: JEFFREY HEIER, MD AND PARISA EMAMI, MD

- 7:30 AM AUTOMATED RETINAL VOLUMETRIC ANALYSIS (ARVA) PROTOCOL USING ARTIFICIAL INTELLIGENCE IN OPTICAL COHERENCE TOMOGRAPHY B-SCANS OF AGE-RELATED MACULAR DEGENERATION STUDY EYES
VLAD DIACONITA, MD, FRCSC
- 7:34 AM FEASIBILITY OF AI-ASSISTED SCREENING FOR CLINICAL TRIALS IN WET AGE-RELATED MACULAR DEGENERATION
LOUIS CAI, MD
- 7:38 AM ANALYSIS OF THE RELATIONSHIP BETWEEN THE DEEP LEARNING-BASED PACHYCHOROID INDEX AND THE PATHOGENESIS OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
MICHIYUKI SAITO, MD, PhD
- 7:42 AM VALIDATION OF LONGITUDINAL PERFORMANCE OF ARTIFICIAL INTELLIGENCE ANALYSIS ON HOME OPTICAL COHERENCE TOMOGRAPHY (OCT)
THEODORE LENG, MD, MS
- 7:46 AM COMBINED DISCUSSION
- 7:50 AM DEEP LEARNING-BASED SEGMENTATION OF GEOGRAPHIC ATROPHY: A MULTI-CENTER, MULTI-DEVICE VALIDATION IN A REAL-WORLD CLINICAL COHORT
HASENIN AL-KHERSAN, MD
- 7:54 AM PREDICTING THE FUTURE OF GA: GOMPERTZ MODELING, DIGITAL TWINS, AND FELLOW EYE COMPARISONS
NIRANJAN MANOHARAN, MD
- 7:58 AM COMBINED DISCUSSION
- 8:02 AM LARGE LANGUAGE MODELS IN THE SCREENING OF DIABETIC RETINOPATHY
S. SAEED MOHAMMADI, MD
- 8:06 AM DISCUSSION
- 8:08 AM NON-INVASIVE PREDICTION OF RETINAL INFLAMMATION IN UVEITIS USING MACHINE LEARNING ON OCT B-SCANS
PARISA EMAMI, MD, MPH
- 8:12 AM DISCUSSION

TUMORS

MODERATORS: TIMOTHY MURRAY, MD AND AMY SCHEFLER, MD, FACS

- 8:14 AM CLONAL HEMATOPOIESIS IN OPHTHALMIC ONCOLOGY INCLUDING UVEAL MELANOMA AND RETINOBLASTOMA
JASMINE FRANCIS, MD, FACS
- 8:19 AM DISCUSSION
- 8:21 AM HIGH DOSE INTRAVITREAL TOPOTECAN (90-180 MICROGRAMS) FOR RECURRENT RETINAL AND SUBRETINAL RETINOBLASTOMA
DAVID ABRAMSON, MD
- 8:26 AM DISCUSSION
- 8:28 AM UVEAL MELANOMA FINE NEEDLE ASPIRATION BIOPSY FOR GENE EXPRESSION PROFILING (GEP): IMPORTANCE OF GEP CLASS 2, 1B AND 1A FOR SURVIVAL PREDICTION
TIMOTHY MURRAY, MD, MBA, FACS
- 8:33 AM DISCUSSION
- 8:35 AM LIQUID BIOPSY PROTEOMICS REVEALS UVEAL MELANOMA TUMOR MICROENVIRONMENT MOLECULES TO GUIDE RATIONAL THERAPIES
PRITHVI MRUTHYUNJAYA, MD, MHS
- 8:40 AM DISCUSSION
- 8:42 AM COMPARISON OF GENETICS AND METASTATIC OUTCOMES OF NEVI UNDERGOING OBSERVATION VERSUS IMMEDIATELY TREATED UVEAL MELANOMA
AMY SCHEFLER, MD FACS
- 8:47 AM DISCUSSION
- 8:49 AM CAN WE ESTIMATE RESULTS OF UVEAL MELANOMA GENETIC TESTING?
CAROL SHIELDS, MD
- 8:54 AM DISCUSSION
- 8:56 AM ENDODIODE LASER WITH VITRECTOMY-TRANSRETINAL BIOPSY (EDL-VITBX) FOR TREATMENT OF T1 AND T2 UVEAL MELANOMA: INITIAL RESULTS OF VISION SPARING, DEFINITIVE LOCAL THERAPY.
SCOTT OLIVER, MD
- 9:01 AM DISCUSSION
- 9:03 AM MORPHO-FUNCTIONAL OUTCOMES OF INTRAVITREAL DEXAMETHASONE VERSUS ANTI-VEGF IN RADIATION MACULAR EDEMA
GIULIA MIDENA, MD, PhD
- 9:07 AM PRE-TREATMENT EXAMINATION FINDINGS IMPACT CLINICAL OUTCOMES IN VITREORETINAL LYMPHOMA
OGUL UNER, MD

- 9:11 AM COMBINED DISCUSSION
- 9:14 AM UNEXPECTEDLY LOW METASTASIS AND DEATH IN UVEAL MELANOMA TREATED WITH PLAQUE AND VITRECTOMY WITH SILICONE OIL
TARA MCCANNEL, MD, PhD
- 9:18 AM EXPERT CONSENSUS ON THE RELATIVE IMPORTANCE OF CLINICAL RISK FACTORS FOR MALIGNANCY OF MELANOCYTIC CHOROIDAL LESIONS
SCOTT WALTER, MD, MSc, FASRS
- 9:22 AM PHOTODYNAMIC THERAPY FOR INDETERMINATE CHOROIDAL MELANOCYTIC LESIONS WITH SUBRETINAL FLUID
FRANCES WU, MD
- 9:26 AM COMBINED DISCUSSION

9:30 AM REFRESHMENT BREAK

SURGERY II

MODERATORS: MARIA BERROCAL, MD AND JASON HSU, MD

- 9:45 AM SURGICAL MANAGEMENT AND OUTCOMES OF LARGE MYOPIC MACULAR HOLES: A GLOBAL MULTICENTER STUDY
TIANYU LIU, MD
- 9:50 AM DISCUSSION
- 9:52 AM SURGICAL OUTCOMES OF VISCOSTRETCH TECHNIQUE FOR ADVANCED MACULAR HOLE REPAIR
MRINALI GUPTA, MD
- 9:57 AM DISCUSSION
- 9:59 AM NOVEL TECHNIQUE FOR EXTREMELY LARGE, CHRONIC MACULAR HOLE CLOSURE: COMBINED ILM PEEL AND SILICONE TIP BACKFLUSH NEEDLE STRETCH HOLE MASSAGE
JOHN MASON, III, MD
- 10:04 AM DISCUSSION
- 10:06 AM INVERTED ILM FLAP TECHNIQUE- 10 YEAR RESULTS
ZOFIA ANNA NAWROCKA (VEL MICHALEWSKA), MD, PhD
- 10:11 AM DISCUSSION
- 10:13 AM FOVEAL CONFIGURATION AFTER AMNIOTIC MEMBRANE TRANSPLANTATION IN COMPLEX MACULAR HOLES
SANG JOON LEE, MD
- 10:18 AM DISCUSSION

- 10:20 AM LYOPHILIZED AMNIOTIC MEMBRANE PATCH IN RETINAL SURGERY: CLINICAL APPLICATIONS AND OUTCOMES
ROBERTA RISSOTTO, MD
- 10:25 AM DISCUSSION
- 10:27 AM CHRONIC CANNABIS USE AND RISK OF POST-OPERATIVE PROLIFERATIVE VITREORETINOPATHY: MATCHED COHORT ANALYSIS
EHSAN RAHIMY, MD
- 10:32 AM DISCUSSION
- 10:34 AM METHOTREXATE FOR EARLY PROLIFERATIVE VITREORETINOPATHY
THANOS PAPAKOSTAS, MD
- 10:39 AM DISCUSSION
- 10:41 AM NETARSUDIL AS A NOVEL THERAPEUTIC FOR PVR
ELLIOTT SOHN, MD
- 10:46 AM RANDOMIZED CLINICAL TRIAL OF TOPICAL NETARSUDIL (RHOPRESSA) TO LOWER THE RISK OF PROLIFERATIVE VITREORETINOPATHY IN HIGH-RISK PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT
JASON HSU, MD
- 10:51 AM COMBINED DISCUSSION

DIABETES II

MODERATORS: MANJOT GILL, MD AND ALEKSANDRA RACHITSKAYA, MD

- 10:55 AM COMPARATIVE EFFICACY OF FARICIMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA AT 1 AND 2 YEARS: A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS
MARK BARAKAT, MD
- 10:59 AM REAL-WORLD EFFICACY AND SAFETY OF FARICIMAB IN DIABETIC MACULAR EDEMA: TWO-YEAR RESULTS OF THE TAHOE STUDY
CARL DANZIG, MD
- 11:03 AM QUANTITATIVE ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY (UWFA) FOR THE ASSESSMENT OF NOVEL BIOMARKERS OF VASCULAR STABILITY WITH FARICIMAB: A YOSEMITE/RHINE POST HOC ANALYSIS
ALEKSANDRA RACHITSKAYA, MD
- 11:07 AM REDUCED HARD EXUDATES (HES) AND MICROANEURYSMS (MAS) WITH FARICIMAB COMPARED WITH AFLIBERCEPT IN YOSEMITE/RHINE USING AUTOMATED SEGMENTATION OF DME LESIONS ON COLOR FUNDUS PHOTOGRAPHY (CFP)
PRETHY RAO, MD MPH
- 11:11 AM TREATMENT RESPONSE AND SAFETY OF FARICIMAB IN UNDERREPRESENTED PATIENTS WITH DME: YEAR 1 RESULTS FROM ELEVATUM IN THE UNITED STATES
MATTHEW CUNNINGHAM, MD

- 11:15 AM COMBINED DISCUSSION
- 11:19 AM IMPACT OF CONTINUOUS DELIVERY VIA THE PORT DELIVERY PLATFORM WITH RANIBIZUMAB (PDS) ON NONPERFUSION AND VASCULAR LEAKAGE IN EYES WITH DIABETIC RETINOPATHY (DR) OR DIABETIC MACULAR EDEMA (DME)
MANJOT GILL, MD
- 11:23 AM IMPACT OF CONTINUOUS DELIVERY VIA THE PORT DELIVERY PLATFORM WITH RANIBIZUMAB (PDS) ON RETINAL FLUID AND THICKNESS FLUCTUATIONS IN PATIENTS WITH DIABETIC MACULAR EDEMA (DME): RESULTS FROM THE PAGODA TRIAL THROUGH YEAR 2
DENNIS MARCUS, MD
- 11:27 AM COMBINED DISCUSSION
- 11:30 AM **RAYMOND MARGHERIO FELLOWSHIP AWARD**
INTRODUCTION: ADRIENNE SCOTT, MD
EVALUATING CLINICAL SIGNS OF REGRESSION IN EYES TREATED WITH INTRAVITREAL BEVACIZUMAB FOR TYPE 1 RETINOPATHY OF PREMATURITY
YUXI ZHENG, MD
- 11:45 AM **J. DONALD M. GASS AWARD: MARK JOHNSON MD**
INTRUDUCTION: SUNIR GARG, MD
GASS-LIGHTING: ILLUMINATING DISEASE PATHOGENESIS ONE PATIENT AT A TIME
MARK JOHNSON, MD
- 12:15 PM **ANNUAL BUSINESS MEETING**
- 1:00 PM **LUNCH**
- 1:45 PM **DESSERT AND POSTER VIEWING SESSION 2**

AMD II

MODERATORS: ANAT LOEWENSTEIN, MD AND DAVID EICHENBAUM, MD

- 2:30 PM PIGMENT EPITHELIAL DETACHMENT OUTCOMES WITH AFLIBERCEPT 8 MG VERSUS AFLIBERCEPT 2 MG IN THE PULSAR TRIAL: A 96-WEEK POST HOC ANALYSIS
MICHAEL SINGER, MD
- 2:34 PM DISCUSSION
- 2:36 PM FIVE-YEAR OUTCOMES IN PDS-TREATED PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) ENROLLED IN THE ARCHWAY-TO-PORTAL TRIALS
CARL AWH, MD
- 2:40 PM LONG-TERM EFFICACY AND SAFETY OF THE FIRST PATIENT COHORT TREATED WITH THE PDS FOR NAMD: RESULTS FROM THE LADDER AND PORTAL EXTENSION TRIALS, WITH PATIENT FOLLOW-UP THROUGH 7 YEARS
ROBERT MITTRA, MD
- 2:44 PM MITIGATING CONJUNCTIVAL EROSIONS IN PATIENTS TREATED WITH THE PDS: SURGICAL MANAGEMENT AND CLINICAL OUTCOMES
MICHAEL KLUFAS, MD

- 2:48 PM IMPACT OF IMPROVEMENTS TO SURGICAL PROCEDURE ON THE INCIDENCE OF ENDOPTHALMITIS AND ASSOCIATED OUTCOMES OF PATIENTS IN THE PORT DELIVERY PLATFORM WITH RANIBIZUMAB CLINICAL DEVELOPMENT PROGRAM
CARL REGILLO, MD
- 2:52 PM COMBINED DISCUSSION
- 2:57 PM FARICIMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: 1-YEAR RESULTS FROM THE PHASE 3B/4 SALWEEN TRIAL
JUNYEOP LEE, MD, PhD
- 3:02 PM DISCUSSION
- 3:04 PM REAL-WORLD EFFICACY AND SAFETY OF FARICIMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 3.5 YEAR RESULTS OF THE TRUCKEE STUDY
VEERAL SHETH, MD, MBA
- 3:09 PM DISCUSSION
- 3:11 PM IXOBEROGENE SOROPARVOVEC INTRAVITREAL GENE THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMd): RESULTS FROM OPTIC AND LUNA TRIALS
DAVID EICHENBAUM, MD
- 3:16 PM IXOBEROGENE SOROPARVOVEC (IXO-VEC) INTRAVITREAL GENE THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMd): 4-YEAR SAFETY AND EFFICACY RESULTS FROM THE OPTIC TRIAL
RISHI SINGH, MD
- 3:21 PM COMBINED DISCUSSION
- 3:24 PM SIX-MONTH FIRST-IN-HUMAN SAFETY AND EFFICACY DATA OF SUBRETINAL NG101 - A NOVEL LOW-DOSE AAV GENE THERAPY FOR WET AMD: A PHASE 1/2A CLINICAL TRIAL
CHRISTOPHER RIEMANN, MD
- 3:29 PM ONE YEAR RESULTS OF A PHASE 2 PHARMACODYNAMIC STUDY: SUBRETINAL DELIVERY OF INVESTIGATIONAL GENE THERAPY ABBV-RGX-314 FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
MURTAZA ADAM, MD
- 3:34 PM COMBINED DISCUSSION
- 3:37 PM **REFRESHMENT BREAK**
- 3:57 PM LATE BREAKERS SESSION 2

AMD III

MODERATORS: CARL REGILLO, MD AND AVNI FINN, MD

- 4:12 PM PIVOTAL TRIAL OUTCOMES FOR THE FIRST EVER AI-ENABLED HOME-BASED OCT CLEARED BY THE US FDA
ANAT LOEWENSTEIN, MD

4:17 PM	DISCUSSION
4:19 PM	FOUR-YEAR OUTCOMES OF FARICIMAB IN NAMD: SAFETY AND EFFICACY RESULTS FROM THE AVONELLE-X LONG-TERM EXTENSION TRIAL ARSHAD KHANANI, MD, MA
4:23 PM	GREATER ANATOMICAL IMPROVEMENTS WITH FARICIMAB VS AFLIBERCEPT 8 WEEKS AFTER INJECTIONS: A TENAYA/LUCERNE POST HOC ANALYSIS AVNI FINN, MD, MBA
4:27 PM	SIX-MONTH OUTCOMES OF INTRAVITREAL FARICIMAB INJECTION FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND ITS RELATIONSHIPS WITH CLINICAL FINDINGS: A MULTICENTER COHORT STUDY FROM J-CREST RYOJI YANAI, MD, PhD
4:31 PM	BASELINE AND EARLY TREATMENT RESPONSE VARIABLES ASSOCIATED WITH FARICIMAB DURABILITY IN TREATMENT-NAÏVE NAMD: TENAYA/LUCERNE POST HOC ANALYSES DEEPAK SAMBHARA, MD
4:35 PM	COMBINED DISCUSSION
4:39 PM	EARLY REAL-WORLD USE OF AFLIBERCEPT 8 MG IN TREATMENT-NAIVE PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) FERHINA ALI, MD MPH
4:43 PM	EARLY INSIGHTS FROM REAL-WORLD USE OF AFLIBERCEPT 8 MG AMONG EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) SWITCHING FROM OTHER ANTI-VEGF AGENTS JIA-HORUNG HUNG,
4:47 PM	CLINICAL CHARACTERISTICS AND OUTCOMES OF PREVIOUSLY TREATED EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION SWITCHED TO EYLEA HD CHIRAG SHAH, MD, MPH
4:51 PM	COMBINED DISCUSSION
4:55 PM	IMPACT OF EARLY STRUCTURAL MARKERS OF ATROPHIC AMD ON RETINAL SENSITIVITY IN THE PROSPECTIVE MULTICENTER PINNACLE STUDY URSULA SCHMIDT-ERFURTH, MD
5:00 PM	DISCUSSION
5:02 PM	SURVEY ON PATTERNS OF INTRAVITREAL COMPLEMENT INHIBITOR USE AMONG RETINA SPECIALISTS. JACLYN KOVACH, MD
5:06 PM	DISCUSSION
5:08 PM	ADJOURN

SCIENTIFIC PROGRAM

SATURDAY, SEPTEMBER 13, 2025

DIABETES III

MODERATORS: BARUCH KUPPERMANN, MD, PHD AND JENNIFER KANG-MIELER, PHD

- 8:00 AM RHONE-X EXTENSION STUDY: CLINICAL IMPROVEMENTS IN EYES WITH DME SWITCHED FROM AFLIBERCEPT TO FARICIMAB
ROGER GOLDBERG, MD, MBA
- 8:04 AM COMBINED DISCUSSION
- 8:06 AM FOLLOW-UP ASSESSMENT OF RETINAL VASCULAR PERMEABILITY AS A BIOMARKER IN DIABETIC SUBJECTS WITH NO DIABETIC RETINOPATHY (DMNODR)
JENNIFER KANG-MIELER, PhD
- 8:10 AM GEOMETRIC PERFUSION DEFICIT (GPD) OF THE RADIAL PERIPAPILLARY CAPILLARY PLEXUS CORRELATES WITH RETINAL PERIPHERY GPD: A NEW WAY OF FOLLOWING RETINAL ISCHEMIA IN DIABETIC EYES
EDOARDO MIDENA, MD, PhD
- 8:14 AM COMBINED DISCUSSION
- 8:16 AM OUTCOMES OF A NONSTEROIDAL ANTI-INFLAMMATORY TOPICAL DROP REGIMEN ON TREATMENT-NAIVE DIABETIC MACULAR EDEMA
RUI WANG, MD
- 8:20 AM DISCUSSION
- 8:22 AM REAL-WORLD STEROID UTILIZATION IN ANTI-VEGF-TREATED DME FROM 2018 TO 2024: A RETROSPECTIVE CLAIMS ANALYSIS
J. FERNANDO AREVALO, MD, PhD, FACS
- 8:27 AM DISCUSSION
- 8:29 AM DEXAMETHASONE INTRAVITREAL INJECTION ELICITS FAST ONSET OF ACTION OF BCVA IN DME PATIENTS
BARUCH KUPPERMANN, MD, PhD
- 8:34 AM DISCUSSION
- 8:36 AM EARLY INSIGHTS FROM REAL-WORLD USE OF AFLIBERCEPT 8 MG AMONG EYES WITH DIABETIC MACULAR EDEMA (DME) SWITCHING FROM OTHER ANTI-VEGF AGENTS
MICHAEL JAVAHERI, MD, Msc
- 8:40 AM DISCUSSION
- 8:42 AM PREDICTORS OF INJECTION NUMBERS IN PATIENTS WITH DIABETIC MACULAR EDEMA (DME) TREATED WITH FARICIMAB PERSONALIZED T&E IN THE PHASE 3 YOSEMITE/RHINE TRIALS
JESSE JUNG, MD

8:46 AM	DISCUSSION
8:48 AM	ASSOCIATION OF PATIENT AGE WITH RESPONSE TO ANTI-VEGF AGENTS FOR TREATMENT OF DIABETIC MACULAR EDEMA LEANNE LABRIOLA, DO, MBA
8:52 AM	DISCUSSION
8:54 AM	EFFECT OF FARICIMAB AND AFLIBERCEPT ON MICROANEURYSMS AFTER LOADING TREATMENT FOR DIABETIC MACULAR EDEMA SHIGEO YOSHIDA, MD, PhD
9:58 AM	DISCUSSION
9:00 AM	SHORT-TERM EFFICACY OF AFLIBERCEPT HD COMPARED TO FARICIMAB-SVOA FOR DIABETIC MACULAR EDEMA BRADLEY SMITH, MD
9:04 AM	DISCUSSION

SURGERY III

MODERATORS: DEAN ELIOTT, MD AND KOUROUS REZAEI, MD

9:06 AM	GENOME-WIDE ASSOCIATION STUDY OF STEROID-INDUCED OCULAR HYPERTENSION (SIOH) STEPHEN SCHWARTZ, MD, MBA
9:10 AM	INTRAOPERATIVE OCT-GUIDED STUDY: EFFECTS OF VITRECTOMY TECHNIQUE MODIFICATIONS AND REAL-TIME INTRAOCULAR PRESSURE DYNAMICS ON SUBRETINAL BLEB VOLUME LEJLA VAJZOVIC, MD
9:15 AM	DISCUSSION
9:17 AM	THREE-DIMENSIONAL RETINAL DISPLACEMENT BEFORE AND AFTER SURGERY FOR MACULAR PUCKER GUIDO RIPANDELLI, MD
9:22 AM	FUNCTIONAL AND ANATOMICAL OUTCOMES IN EYES WITH IDIOPATHIC EPIRETINAL MEMBRANES FOLLOWING SURGICAL REMOVAL. RESULTS AT 5 YEARS OF THE PAN AMERICAN COLLABORATIVE RETINA STUDY (PACORES) GROUP LIHTEH WU, MD
9:27 AM	COMBINED DISCUSSION
9:31 AM	SURGICALLY INDUCED ASTIGMATISM WITH THE AKREOS AO60 SCLERAL FIXATED INTRAOCULAR LENS ROYCE CHEN, MD
9:36 AM	DISCUSSION
9:38 AM	LONG-TERM OUTCOMES OF PARS PLANA VITRECTOMY AND GORE-TEX SUTURED SCLERAL-FIXATED INTRAOCULAR LENSES OMESH GUPTA, MD, MBA

9:43 AM	DISCUSSION
9:45 AM	LONG TERM OUTCOMES AFTER IMPLANTATION OF SUTURELESS INTRASCLERAL FIXATION LENSES FOLLOWING COMPLEX CATARACT SURGERY – A SINGLE CENTER RETROSPECTIVE STUDY VIREN GOVINDARAJU, MD
9:49 AM	DISCUSSION
9:51 AM	EXPERIENCE WITH ASSISTANT-FREE WIDE ANGLE SURGICAL CONTACT LENSES FOR VISUALIZATION DURING VITRECTOMY EDWIN RYAN, MD
9:56 AM	DISCUSSION
9:58 AM	SHIFTING PRACTICE PATTERNS IN VITREORETINAL SURGERY: GEOGRAPHIC AND TEMPORAL TRENDS IN VOLUME, REIMBURSEMENT, AND SURGICAL SITE AMONG MEDICARE BENEFICIARIES (2000–2022) STEPHANIE ENGELHARD, MD
10:03 AM	DISCUSSION
10:05 AM	FUNCTIONAL ASSESSMENT OF A NOVEL 27-GAUGE MULTI-SPOT LASER PROBE IN A SURGICAL SIMULATION BIONIKO EYE MODEL KOUROUS REZAEI, MD
10:10 AM	DISCUSSION
10:12 AM	IMPACT OF THE NEXT GENERATION OF VITREORETINAL-CATARACT SYSTEM ON VITREORETINAL SURGERY EFFICIENCY: A PROSPECTIVE, COMPARATIVE, OBSERVATIONAL TIME AND MOTION STUDY MIGUEL BUSQUETS, MD, FACS, FASRS
10:17 AM	DISCUSSION
10:19 AM	LONG TERM EFFECTS OF PARS PLANA VITRECTOMY ON INTRAOCULAR PRESSURE AND ANTIHYPERTENSIVE DROP USAGE YASHA MODI, MD
10:22 AM	DISCUSSION
10:24 AM	FREQUENCY OF ANTI-VEGF INJECTIONS BEFORE AND AFTER PARS PLANA VITRECTOMY IN EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION MICHAEL COHEN, MD
10:27 AM	DISCUSSION
10:29 AM	REFRESHMENT BREAK

AMD IV

MODERATORS: SHARON FEKRAT, MD AND VICTOR GONZALEZ, MD

- 10:49 AM MULTIMODAL IMAGING DETERMINANTS OF CONTRAST SENSITIVITY REDUCTION IN GEOGRAPHIC ATROPHY
JOHN MILLER, MD
- 10:54 AM DISCUSSION
- 10:56 AM VIRTUAL REALITY-BASED VISUAL FIELD TESTING VERSUS MICROPERIMETRY IN GEOGRAPHIC ATROPHY
JESSE SMITH, MD
- 11:00 AM DISCUSSION
- 11:02 AM IS THE CONFIRMED LOSS OF 15 OR MORE ETDRS LETTERS A MEANINGFUL AND CONSISTENT INDICATOR OF CLINICALLY RELEVANT VISUAL FUNCTION LOSS IN DRY AMD?
DAVID LALLY, MD
- 11:06 AM DISCUSSION
- 11:08 AM LIGHTSITE IIIB: AN OPEN-LABEL, PROSPECTIVE, MULTI-CENTER EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF PHOTOBIMODULATION IN SUBJECTS WITH DRY AGE-RELATED MACULAR DEGENERATION
RICHARD ROSEN, MD, ScD
- 11:14 AM DISCUSSION
- 11:17 AM EARLY VERSUS DELAYED PEGCETACOPLAN TREATMENT FOR GA SECONDARY TO AMD: 48 MONTH RESULTS FROM OAKS, DERBY, AND GALE OPEN-LABEL EXTENSION
MATHEW MACCUMBER, MD, PhD
- 11:21 AM FACTORS AFFECTING GEOGRAPHIC ATROPHY PROGRESSION AND TREATMENT RESPONSE TO PEGCETACOPLAN
NATHAN STEINLE, MD
- 11:25 AM IMPACT OF AREDS ORAL MICRONUTRIENT SUPPLEMENTATION ON GEOGRAPHIC ATROPHY PROGRESSION: INSIGHTS FROM THE PHASE 3 OAKS AND DERBY TRIALS
SHARON FEKRAT, MD
- 11:29 AM COMBINED DISCUSSION
- 11:32 AM BIOMARKER BASED EFFICACY ANALYSIS OF INTRAVITREAL CFH SUPPLEMENTATION IN A PHASE 2 TRIAL
DAVID BROWN, MD
- 11:37 AM DISCUSSION
- 11:39 AM MACULAR ATROPHY RISK ASSOCIATED TO ANTI-VEGF TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
MAJDA HADZIAHMETOVIC, MD

11:44 AM	DISCUSSION
11:46 AM	GEOGRAPHIC ATROPHY PROGRESSION RATES IN EYES WITH PRE-EXISTING WET AGE-RELATED MACULAR DEGENERATION TREATED WITH PEGCETACOPLAN JINGWEN (ALICIA) ZHANG, MBBS
11:50 PM	DISCUSSION
11:52 PM	RELATIONSHIP OF FUTURE VISION LOSS TO BASELINE CENTRAL ELLIPSOID ZONE INTEGRITY FEATURES IN THE GATHER CLINICAL TRIALS KATHERINE TALCOTT, MD
11:56 AM	DISCUSSION
11:58 AM	SAFETY, TOLERABILITY, AND PROPERTIES OF NOVEL C3 INHIBITOR BI-C IN PATIENTS WITH GA BRIAN BERGER, MD
12:02 PM	DISCUSSION
12:04 PM	TRANSPLANT OF INDUCED PLURIPOTENT STEM CELL-DERIVED RETINAL PIGMENT EPITHELIUM STRIPS FOR AGE-RELATED MACULAR DEGENERATION AND RETINITIS PIGMENTOSA YOKO OZAWA, MD, PhD
12:08 PM	RENEW, A PHASE 3 CLINICAL TRIAL EVALUATING ELAMIPRETIDE IN DRY AGE-RELATED MACULAR DEGENERATION: STUDY DESIGN AND PATIENT BASELINE DEMOGRAPHICS VICTOR GONZALEZ, MD
12:12 PM	A PHASE 3 STUDY OF SAFETY AND EFFICACY OF SUBCUTANEOUSLY ADMINISTERED POZELIMAB IN COMBINATION WITH CEMDISIRAN OR SUBCUTANEOUS CEMDISIRAN ALONE IN PATIENTS WITH GEOGRAPHIC ATROPHY: THE SIENNA STUDY DESIGN MICHAEL IP, MD
12:16 PM	COMBINED DISCUSSION
12:20 PM	ADJOURN